|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000215788 |
Summary for TNFRSF25 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000215788 | Gene symbol | TNFRSF25 |
| Gene name | TNF receptor superfamily member 25 | |
| HGNC | 11910 | |
| Entrez ID | 8718 | |
| Gene type | protein_coding | |
| Synonyms | TNFRSF25|DR3|TRAMP|WSL-1|LARD|WSL-LR|DDR3|TR3|APO-3 | |
| UniProtAcc | Q93038 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for TNFRSF25 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TNFRSF25 | 3.56e+02 | 1.44e+00 | 2.46e-01 | 5.83e+00 | 5.56e-09 | 5.18e-08 | THCA |
| TNFRSF25 | 9.16e+02 | 1.30e+00 | 1.81e-01 | 7.17e+00 | 7.43e-13 | 6.53e-12 | HNSC |
| TNFRSF25 | 1.02e+03 | 2.18e+00 | 2.96e-01 | 7.35e+00 | 1.99e-13 | 8.23e-12 | BLCA |
| TNFRSF25 | 1.52e+03 | 1.55e+00 | 3.29e-01 | 4.71e+00 | 2.46e-06 | 4.98e-05 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TNFRSF25 | 7.87e+02 | 1.12e+00 | 3.72e-01 | 3.02e+00 | 2.51e-03 | 7.67e-03 | READ |
Top |
Sex-biased somatic mutation for TNFRSF25 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TNFRSF25 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| SARC | cg15205428 | chr1:6465991 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 5.26e-01 | 4.21e-01 | 2.70e+00 | 6.99e-03 | 1.45e-02 | 1.05e-01 |
| KICH | cg02084087 | chr1:6465989 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 4.11e-01 | 5.81e-01 | -2.14e+00 | 3.22e-02 | 4.37e-02 | -1.71e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg03893150 | chr1:6466265 | CGI:chr1:6466114-6466361 | promoter | 2.91e-01 | 4.05e-01 | -4.10e+00 | 4.08e-05 | 9.30e-05 | -1.14e-01 |
| THCA | cg11756870 | chr1:6466013 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 2.90e-01 | 1.74e-01 | 3.87e+00 | 1.10e-04 | 6.40e-04 | 1.17e-01 |
| LUSC | cg15205428 | chr1:6465991 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 5.55e-01 | 2.72e-01 | 3.56e+00 | 3.70e-04 | 1.38e-03 | 2.84e-01 |
| LUSC | cg23114616 | chr1:6466338 | CGI:chr1:6466114-6466361 | promoter | 6.34e-01 | 4.92e-01 | 3.28e+00 | 1.04e-03 | 2.67e-03 | 1.42e-01 |
| LUSC | cg02084087 | chr1:6465989 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 6.42e-01 | 4.23e-01 | 3.08e+00 | 2.10e-03 | 4.33e-03 | 2.19e-01 |
| LUSC | cg11756870 | chr1:6466013 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 4.50e-01 | 2.34e-01 | 3.59e+00 | 3.26e-04 | 1.28e-03 | 2.16e-01 |
| LUSC | cg03893150 | chr1:6466265 | CGI:chr1:6466114-6466361 | promoter | 4.36e-01 | 2.13e-01 | 3.67e+00 | 2.43e-04 | 1.08e-03 | 2.23e-01 |
| COAD | cg15205428 | chr1:6465991 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 6.79e-01 | 4.12e-01 | 4.75e+00 | 2.02e-06 | 1.88e-05 | 2.67e-01 |
| COAD | cg10059687 | chr1:6466069 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 6.02e-01 | 4.36e-01 | 4.88e+00 | 1.04e-06 | 1.23e-05 | 1.66e-01 |
| COAD | cg23114616 | chr1:6466338 | CGI:chr1:6466114-6466361 | promoter | 7.15e-01 | 5.52e-01 | 4.39e+00 | 1.11e-05 | 6.36e-05 | 1.64e-01 |
| COAD | cg02084087 | chr1:6465989 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 7.71e-01 | 5.48e-01 | 4.56e+00 | 5.17e-06 | 3.62e-05 | 2.23e-01 |
| COAD | cg11756870 | chr1:6466013 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 5.75e-01 | 3.83e-01 | 4.68e+00 | 2.80e-06 | 2.35e-05 | 1.92e-01 |
| COAD | cg04500986 | chr1:6466471 | CGI:chr1:6466114-6466361 | promoter | 7.83e-01 | 6.81e-01 | 4.17e+00 | 3.11e-05 | 1.40e-04 | 1.02e-01 |
| KIRP | cg02988775 | chr1:6464582 | CGI:chr1:6466114-6466361 | promoter,gene body,CDS,UTR,exon | 4.92e-01 | 6.26e-01 | -4.02e+00 | 5.84e-05 | 1.64e-04 | -1.34e-01 |
| CHOL | cg02084087 | chr1:6465989 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 6.45e-01 | 4.57e-01 | 1.99e+00 | 4.65e-02 | 4.65e-02 | 1.88e-01 |
| CHOL | cg11756870 | chr1:6466013 | CGI:chr1:6466114-6466361 | promoter,exon,gene body | 4.72e-01 | 2.94e-01 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 1.78e-01 |
| CHOL | cg03893150 | chr1:6466265 | CGI:chr1:6466114-6466361 | promoter | 4.50e-01 | 2.86e-01 | 2.36e+00 | 1.83e-02 | 2.92e-02 | 1.64e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg02988775 | chr1:6464582 | CGI:chr1:6466114-6466361 | promoter,gene body,CDS,UTR,exon | 6.20e-01 | 7.69e-01 | -8.85e+00 | 8.67e-19 | 4.25e-18 | -1.49e-01 |
| BRCA | cg00087884 | chr1:6465491 | CGI:chr1:6466114-6466361 | promoter,gene body,CDS,UTR,exon | 5.52e-01 | 6.54e-01 | -9.17e+00 | 4.68e-20 | 2.54e-19 | -1.02e-01 |
| THCA | cg02988775 | chr1:6464582 | CGI:chr1:6466114-6466361 | promoter,gene body,CDS,UTR,exon | 4.93e-01 | 5.94e-01 | -5.30e+00 | 1.17e-07 | 9.72e-07 | -1.01e-01 |
| HNSC | cg16681526 | chr1:6466409 | CGI:chr1:6466114-6466361 | promoter | 6.78e-01 | 7.82e-01 | -2.02e+00 | 4.29e-02 | 4.48e-02 | -1.04e-01 |
| KIRP | cg23114616 | chr1:6466338 | CGI:chr1:6466114-6466361 | promoter | 6.62e-01 | 5.37e-01 | 2.47e+00 | 1.35e-02 | 2.06e-02 | 1.24e-01 |
Top |
Exon skipping events with PSI in TCGA for TNFRSF25 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TNFRSF25 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TNFRSF25 |
| TFs related to TNFRSF25. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | PLAGL2 | TNFRSF25 | 3.25e+00 | 5.83e-03 | 4.64e+00 | 9.86e-01 | Female-biased |
| SKCM | PLAGL2 | TNFRSF25 | 4.50e+00 | 9.83e-01 | 3.21e+00 | 4.95e-03 | Male-biased |
| TNFRSF25 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for TNFRSF25 |
| RBPs related to ES in TNFRSF25. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| TNFRSF25 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
 | Gene ID: ENSG00000215788 |
| SNP ID: rs3007420 | |
| Position to Gene: enhancer | |
| Male Effect: - | |
| Female Effect: 0.153144484213915 |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs753380 | chr1:7868292:G:C | - | 0.177655732289813 | 0.0451992281700431 | GBM | Female-baised eQTL |
| rs743999 | chr1:7868305:G:A | - | 0.177655732289813 | 0.0451992281700431 | GBM | Female-baised eQTL |
| rs12757238 | chr1:7869802:T:C | - | 0.177655732289813 | 0.0451992281700431 | GBM | Female-baised eQTL |
| rs6684933 | chr1:7872930:A:G | - | 0.177655732289813 | 0.0451992281700431 | GBM | Female-baised eQTL |
| rs6688115 | chr1:7872844:C:T | - | 0.178436281974244 | 0.0468873462854691 | GBM | Female-baised eQTL |
| rs8014 | chr1:1055604:G:A | - | -0.197134721711862 | 0.025719963771709 | KIRP | Female-baised eQTL |
| rs2710885 | chr1:1056602:T:C | - | -0.197134721711862 | 0.025719963771709 | KIRP | Female-baised eQTL |
| rs2245754 | chr1:1056947:C:T | - | -0.197134721711862 | 0.025719963771709 | KIRP | Female-baised eQTL |
| rs17028753 | chr1:5757414:A:T | - | 0.182343064361095 | 0.000540346421363528 | LIHC | Female-baised eQTL |
| rs17035599 | chr1:10704179:C:T | - | 0.161763396187636 | 0.00133569625336336 | LIHC | Female-baised eQTL |
| rs117824461 | chr1:10704393:C:T | - | 0.160851484093083 | 0.00279034551888135 | LIHC | Female-baised eQTL |
| rs75010668 | chr1:14482188:C:T | - | 0.142801097564183 | 0.0272156730577463 | LIHC | Female-baised eQTL |
| rs117773625 | chr1:14483724:C:T | - | 0.142801097564183 | 0.0272156730577463 | LIHC | Female-baised eQTL |
| rs74341976 | chr1:14483821:T:A | - | 0.142801097564183 | 0.0272156730577463 | LIHC | Female-baised eQTL |
| rs78431676 | chr1:14487334:T:A | - | 0.142801097564183 | 0.0272156730577463 | LIHC | Female-baised eQTL |
| rs3128465 | chr1:12724080:A:G | - | -0.0972858106911895 | 0.029671274756911 | LIHC | Female-baised eQTL |
| rs16850332 | chr1:14470051:T:A | - | 0.135576953307194 | 0.040152906354376 | LIHC | Female-baised eQTL |
| rs80030164 | chr1:5756899:G:A | - | 0.174520674918229 | 0.0497642860033708 | LIHC | Female-baised eQTL |
| rs3007420 | chr1:6469763:G:C | enhancer | 0.153144484213915 | 3.80903429510428e-08 | LGG | Female-baised eQTL |
| rs11121423 | chr1:9450467:T:C | - | -0.0949837222096759 | 0.0020594032909414 | LGG | Female-baised eQTL |
| rs10927407 | chr1:14302786:C:A | - | 0.125867380363509 | 0.0242416965768205 | LGG | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12041042 | chr1:2982774:G:A | - | 0.0621999003548858 | 0.00207659909286369 | LIHC | Male-baised eQTL |
| rs189576680 | chr1:4211239:A:G | - | 0.0519033765136314 | 0.0289495946797692 | LIHC | Male-baised eQTL |
| rs72629470 | chr1:3004718:G:A | - | 0.0413701669140517 | 0.0365139359347464 | LIHC | Male-baised eQTL |
| rs946176 | chr1:3008933:C:T | - | 0.0409800845943947 | 0.0387461936129199 | LIHC | Male-baised eQTL |
| rs72629471 | chr1:3004853:C:G | - | 0.040912611483391 | 0.0397113251385576 | LIHC | Male-baised eQTL |
| rs12025167 | chr1:3003455:C:T | - | 0.0406069598329065 | 0.0412861746352652 | LIHC | Male-baised eQTL |
| rs12028094 | chr1:3005763:C:T | - | 0.0404402169029909 | 0.0433422554939942 | LIHC | Male-baised eQTL |
| rs12022456 | chr1:3003478:G:A | - | 0.0404116374534207 | 0.04349555725472 | LIHC | Male-baised eQTL |
| rs118185327 | chr1:4381392:A:G | - | 0.106381948231568 | 0.0114950620302371 | LGG | Male-baised eQTL |
| rs144379770 | chr1:4381457:C:T | - | 0.106381948231568 | 0.0114950620302371 | LGG | Male-baised eQTL |
| rs72632704 | chr1:4374122:G:A | - | 0.105931331304883 | 0.0204575593798257 | LGG | Male-baised eQTL |
| rs349416 | chr1:4395636:A:C | - | 0.053649303803345 | 0.00941738007361993 | LUAD | Male-baised eQTL |
| rs349400 | chr1:4402400:T:G | - | 0.0535815286491926 | 0.0101467692068788 | LUAD | Male-baised eQTL |
| rs349399 | chr1:4400420:C:G | - | 0.0532182999105937 | 0.0105656473618479 | LUAD | Male-baised eQTL |
| rs349398 | chr1:4399236:A:G | - | 0.05285964773468 | 0.0119571509738617 | LUAD | Male-baised eQTL |
| rs349393 | chr1:4359760:A:C | - | 0.0533966057877895 | 0.0166268763356512 | LUAD | Male-baised eQTL |
| rs102083 | chr1:4359845:A:T | - | 0.0509524984323313 | 0.0266784844545557 | LUAD | Male-baised eQTL |
| rs102085 | chr1:4359894:G:A | - | 0.0509524984323313 | 0.0266784844545557 | LUAD | Male-baised eQTL |
| rs2924863 | chr1:13471243:T:G | - | 0.108209921030076 | 0.0267159513114254 | LUAD | Male-baised eQTL |
| rs349417 | chr1:4398008:T:C | - | 0.0485929986648576 | 0.048673310019846 | LUAD | Male-baised eQTL |
| rs349415 | chr1:4395355:G:C | - | 0.0490999670241649 | 0.0489743403998062 | LUAD | Male-baised eQTL |
| rs9662275 | chr1:9440581:G:A | - | 0.108739949841145 | 0.045331796157123 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000215788 |
| CpG Site: cg10059687 | |
| Position to Gene: gene,exon,promoter | |
| Male Effect: -0.215466452858113 | |
| Female Effect: - | |
 | Gene ID: ENSG00000215788 |
| CpG Site: cg10059687 | |
| Position to Gene: gene,exon,promoter | |
| Male Effect: - | |
| Female Effect: -0.433614274649847 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10059687 | chr1:6466069 | gene,exon,promoter | -0.215466452858113 | 4.787244765309e-07 | -0.4009046277442327 | 5.10533715315889e-10 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10059687 | chr1:6466069 | gene,exon,promoter | -0.433614274649847 | 9.91556325901695e-13 | -0.6740505984690092 | 5.98489112236376e-17 | STAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TNFRSF25 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
